Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Income Tax Provision 5 year CAGR for the year ending December 31, 2022

Icosavax Inc Income Tax Provision 5 year CAGR is NA for the year ending December 31, 2022. Income Tax Provision is the amount of income tax expenses recorded by a company in a given period. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Icosavax Inc Income Tax Provision for the year ending December 31, 2021 was USD 1.03 M, a 210.57% change year over year.
Icosavax Inc Income Tax Provision for the year ending December 31, 2020 was USD 331.00 K, a 427.72% change year over year.
Icosavax Inc Income Tax Provision for the year ending December 31, 2019 was USD -101.00 K.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends